LU92568I2 - Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir - Google Patents
Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir Download PDFInfo
- Publication number
- LU92568I2 LU92568I2 LU92568C LU92568C LU92568I2 LU 92568 I2 LU92568 I2 LU 92568I2 LU 92568 C LU92568 C LU 92568C LU 92568 C LU92568 C LU 92568C LU 92568 I2 LU92568 I2 LU 92568I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- simeprevir
- salt
- including sodium
- sodium
- sodium simeprevir
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107074 | 2005-07-29 | ||
EP05107417 | 2005-08-11 | ||
EP06101280 | 2006-02-03 | ||
EP06778071A EP1912999B1 (fr) | 2005-07-29 | 2006-07-28 | Inhibiteurs macrocycliques du virus de l'hépatite c |
PCT/EP2006/064820 WO2007014926A1 (fr) | 2005-07-29 | 2006-07-28 | Inhibiteurs macrocycliques du virus de l'hépatite c |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92568I2 true LU92568I2 (fr) | 2015-10-29 |
Family
ID=37067620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92568C LU92568I2 (fr) | 2005-07-29 | 2014-10-07 | Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir |
Country Status (41)
Country | Link |
---|---|
US (9) | US8148399B2 (fr) |
EP (3) | EP2322516B1 (fr) |
JP (1) | JP4797067B2 (fr) |
KR (1) | KR101059419B1 (fr) |
CN (3) | CN103030636B (fr) |
AP (1) | AP2406A (fr) |
AR (1) | AR055359A1 (fr) |
AT (1) | ATE494288T1 (fr) |
AU (1) | AU2006274865B2 (fr) |
BR (1) | BRPI0614654B1 (fr) |
CA (1) | CA2616580C (fr) |
CR (1) | CR9783A (fr) |
CY (3) | CY1112006T1 (fr) |
DE (1) | DE602006019439D1 (fr) |
DK (2) | DK1912999T3 (fr) |
EA (1) | EA015131B1 (fr) |
EC (1) | ECSP088150A (fr) |
ES (1) | ES2555230T3 (fr) |
GT (1) | GT200600339A (fr) |
HK (2) | HK1116771A1 (fr) |
HN (1) | HN2008000134A (fr) |
HR (2) | HRP20110237T1 (fr) |
HU (2) | HUE027156T2 (fr) |
IL (2) | IL188227A (fr) |
LU (1) | LU92568I2 (fr) |
ME (2) | ME02415B (fr) |
MY (1) | MY144217A (fr) |
NI (1) | NI200800036A (fr) |
NO (2) | NO342393B1 (fr) |
NZ (1) | NZ564550A (fr) |
PE (1) | PE20070211A1 (fr) |
PL (2) | PL1912999T3 (fr) |
PT (2) | PT2322516E (fr) |
RS (2) | RS51743B (fr) |
SG (1) | SG163617A1 (fr) |
SI (2) | SI2322516T1 (fr) |
SV (1) | SV2008002642A (fr) |
TW (1) | TWI358411B (fr) |
UY (1) | UY29703A1 (fr) |
WO (1) | WO2007014926A1 (fr) |
ZA (1) | ZA200800857B (fr) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
NZ548740A (en) | 2004-01-30 | 2010-06-25 | Medivir Ab | HCV NS-3 Serine protease inhibitors |
TWI393723B (zh) * | 2005-07-29 | 2013-04-21 | Tibotec Pharm Ltd | C型肝炎病毒之大環抑制劑(九) |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PE20070343A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
PE20070210A1 (es) * | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
CA2617096C (fr) * | 2005-07-29 | 2013-12-24 | Tibotec Pharmaceuticals Ltd. | Inhibiteurs macrocycliques du virus de l'hepatite c |
BRPI0614620A2 (pt) * | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para preparar os referidos compostos, combinação e composição farmacêutica |
ES2373685T3 (es) | 2005-07-29 | 2012-02-07 | Tibotec Pharmaceuticals | Inhibidores macrocíclicos del virus de la hepatitis c. |
MY142972A (en) * | 2005-07-29 | 2011-01-31 | Tibotec Pharm Ltd | Macrocyclic inhibitors of hepatitis c virus |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN101426774B (zh) | 2006-04-19 | 2012-04-25 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
US20090227491A1 (en) * | 2006-07-07 | 2009-09-10 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2661338C (fr) | 2006-11-17 | 2015-05-12 | Tibotec Pharmaceuticals Ltd. | Inhibiteurs macrocycliques du virus de l'hepatite c |
PT2118098E (pt) * | 2007-02-01 | 2014-12-09 | Janssen R & D Ireland | Formas polimórficas de um inibidor macrocíclico do hcv |
DE602008001251D1 (de) * | 2007-02-01 | 2010-06-24 | Tibotec Pharm Ltd | Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
CA2703106C (fr) * | 2007-10-24 | 2015-12-01 | Astellas Pharma Inc. | Derives d'azolecarboxamide comme inhibiteurs de trka |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
WO2009070692A1 (fr) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de sérine protéase de l'hépatite c macrocycliques, dérivés de la proline, substitués en c5 |
US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
AR070413A1 (es) | 2008-02-04 | 2010-04-07 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de proteasa de serina |
JP5490778B2 (ja) | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009148923A1 (fr) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l’hépatite c |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
BRPI0918653A2 (pt) | 2008-09-17 | 2015-12-01 | Boehringer Ingelheim Int | combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. |
WO2010031832A2 (fr) * | 2008-09-18 | 2010-03-25 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique |
TW201023858A (en) * | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
UY32332A (es) | 2008-12-22 | 2010-07-30 | Gilead Sciences Inc | Compuestos macrocíclicos sus prodrogas, n-óxidos, sales de adición, aminas cuaternarias, complejos de metales y formas estereoquímicamente isoméricas puras. |
EP2376514A2 (fr) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Analogues de nucléoside |
TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
EP2376088B1 (fr) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée |
RU2016120007A (ru) | 2008-12-23 | 2018-11-13 | Орто-Макнейл-Янссен Фармасьютикалз, Инк | Способы и промежуточные соединения для получения макроциклического ингибитора протеазы вируса гепатита c |
AU2010219160B2 (en) * | 2009-02-27 | 2015-12-10 | Ortho-Mcneil-Janssen Pharmaceuticals Inc | Amorphous salt of a macrocyclic inhibitor of HCV |
US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
WO2010107965A1 (fr) * | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Procédé de préparation de sulfonyle quinoléines |
JP2012523419A (ja) * | 2009-04-08 | 2012-10-04 | イデニク プハルマセウティカルス,インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
IN2012DN02693A (fr) * | 2009-09-28 | 2015-09-04 | Intermune Inc | |
WO2011053617A1 (fr) | 2009-10-30 | 2011-05-05 | Boehringer Ingelheim International Gmbh | Régimes posologiques pour une thérapie en combinaison contre le vhc comprenant bi201335, l'interféron alpha et la ribavirine |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
EP2504343A4 (fr) * | 2009-11-24 | 2013-04-17 | Boehringer Ingelheim Int | Composés inhibiteurs de l'hépatite c |
MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
US9586893B2 (en) | 2010-03-16 | 2017-03-07 | Janssen Pharmaceuticals | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV |
UY33311A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidatos de nucleosidos |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
UY33312A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidato de nucleosido de purina |
KR20130057990A (ko) * | 2010-04-13 | 2013-06-03 | 얀센 파마슈티칼즈, 인코포레이티드 | 마크로사이클릭 hcv 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물 |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
CA2821340A1 (fr) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de phenanthridine de serine protease d'hepatite c |
WO2012092409A2 (fr) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Inhibiteurs macrocycliques de sérine protéase d'hépatite c |
AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
EP2755944B1 (fr) * | 2011-09-16 | 2017-06-14 | Sanofi | Dérivés de bi-aryle, leur préparation et leur application thérapeutique |
AR087993A1 (es) | 2011-09-22 | 2014-04-30 | Janssen Pharmaceuticals Inc | Procesos e intermediarios para la preparacion de un inhibidor macrociclico de la proteasa del hcv |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
CA2811250C (fr) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methodes de traitement du vhc |
GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
EA201490892A1 (ru) | 2011-10-28 | 2014-08-29 | Янссен Фармасьютикалз, Инк. | Усовершенствованный способ получения промежуточного соединения макроциклического ингибитора tmc 435 протеазы |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CA2863002A1 (fr) | 2012-01-11 | 2013-07-18 | Abbvie Inc. | Procedes de preparation d'inhibiteurs de protease du vhc |
CN103387509B (zh) * | 2012-05-11 | 2016-06-08 | 重庆博腾制药科技股份有限公司 | 一种hcv蛋白酶抑制剂中间体的制备方法 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
AU2013311025A1 (en) * | 2012-08-31 | 2015-02-26 | Janssen Pharmaceuticals, Inc. | Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir |
MX2015004411A (es) | 2012-10-08 | 2016-04-06 | Abbvie Inc | Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc). |
KR20150074051A (ko) | 2012-10-19 | 2015-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | C형 간염 바이러스 억제제 |
WO2014070964A1 (fr) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (fr) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
BR112015021768A2 (pt) | 2013-03-15 | 2016-02-02 | Gilead Sciences Inc | inibidores do vírus da hepatite c |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
UA117375C2 (uk) | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
EP3046924A1 (fr) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
US20160271160A1 (en) | 2013-10-17 | 2016-09-22 | Medivir Ab | Hcv polymerase inhibitors |
WO2015103490A1 (fr) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Formes galéniques antivirales solides |
CN104995189B (zh) * | 2014-01-21 | 2017-03-29 | 杭州普晒医药科技有限公司 | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 |
WO2015134560A1 (fr) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015180253A1 (fr) * | 2014-05-29 | 2015-12-03 | 杭州普晒医药科技有限公司 | Forme cristalline d'un médicament contre le virus de l'hépatite c, son procédé de préparation, composition pharmaceutique et son utilisation |
CN105237528B (zh) * | 2014-06-09 | 2019-06-04 | 深圳翰宇药业股份有限公司 | Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法 |
CN105175406B (zh) * | 2014-06-09 | 2019-06-04 | 深圳翰宇药业股份有限公司 | Hcv抑制剂的中间体以及由其制备hcv抑制剂的方法 |
MA41812A (fr) | 2015-03-27 | 2018-01-30 | Janssen Pharmaceuticals Inc | Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc |
CZ2015220A3 (cs) * | 2015-03-27 | 2016-10-05 | Zentiva, K.S. | Amorfní sůl makrocyklického inhibitoru viru hepatitidy C |
WO2016177625A1 (fr) | 2015-05-04 | 2016-11-10 | Sandoz Ag | Siméprévir potassique amorphe |
WO2017064680A1 (fr) | 2015-10-16 | 2017-04-20 | Lupin Limited | Procédé amélioré de préparation du siméprévir de sodium et son intermédiaire |
CN105503851B (zh) * | 2015-12-09 | 2017-06-23 | 重庆润生科技有限公司 | 一种烯基噻唑衍生物的制备方法 |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
CN108368105B (zh) * | 2016-08-12 | 2021-06-29 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的喹啉化合物及其药物组合物及应用 |
EP3999091A1 (fr) | 2019-07-15 | 2022-05-25 | MedImmune Limited | Systèmes tripartites pour la dimérisation de protéines et procédés d'utilisation |
WO2021209563A1 (fr) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
CA1283906C (fr) | 1983-05-09 | 1991-05-07 | Makoto Sunagawa | COMPOSE DE .beta.-LACTAM ET PROCEDE DE PRODUCTION |
GB8929070D0 (en) | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
DE69332616T2 (de) | 1992-12-29 | 2003-11-06 | Abbott Laboratories, Abbott Park | Hemmer der retroviralen Protease |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5831108A (en) * | 1995-08-03 | 1998-11-03 | California Institute Of Technology | High metathesis activity ruthenium and osmium metal carbene complexes |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
AU723730B2 (en) | 1996-04-23 | 2000-09-07 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of IMPDH enzyme |
HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
WO1998040381A1 (fr) | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de l'enzyme impdh |
ATE283865T1 (de) | 1997-08-11 | 2004-12-15 | Boehringer Ingelheim Ca Ltd | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
DE69829381T2 (de) | 1997-08-11 | 2006-04-13 | Boehringer Ingelheim (Canada) Ltd., Laval | Hepatitis c inhibitor peptide |
WO1999051613A1 (fr) | 1998-04-03 | 1999-10-14 | Medivir Ab | Promedicaments de produits pharmaceutiques contenant du phosphore |
US6038157A (en) | 1998-05-28 | 2000-03-14 | Inductotherm Corp. | Fault tolerant power supply circuit |
US6639053B1 (en) | 1998-06-24 | 2003-10-28 | Tetsuya Toyoda | HCV-derived RNA polymerase gene |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
ES2405316T3 (es) | 1999-03-19 | 2013-05-30 | Vertex Pharmaceuticals Incorporated | Inhibidores de la enzima IMPDH |
DE19915178A1 (de) | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
WO2001074768A2 (fr) | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
DE60119968T2 (de) | 2000-11-20 | 2007-01-18 | Bristol-Myers Squibb Co. | Hepatitis c tripeptid inhibitoren |
ATE539744T1 (de) | 2001-10-24 | 2012-01-15 | Vertex Pharma | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2473070C (fr) | 2002-01-23 | 2009-10-13 | Schering Corporation | Composes de proline utilises en tant qu'inhibiteurs de la serine protease ns3 dans le traitement d'une infection par le virus de l'hepatite c |
CA2369711A1 (fr) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Peptides macrocycliques qui agissent contre le virus de l'hepatite c |
US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2370396A1 (fr) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Tri-peptides inhibiteur de l'hepatite c |
CA2369970A1 (fr) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Tri-peptides inhibiteur de l'hepatite c |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
PL373399A1 (en) | 2002-04-11 | 2005-08-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
DE60336550D1 (de) | 2002-05-20 | 2011-05-12 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
JP4312711B2 (ja) | 2002-05-20 | 2009-08-12 | ブリストル−マイヤーズ スクイブ カンパニー | ヘテロ環式スルホンアミドc型肝炎ウイルス阻害剤 |
AUPS328002A0 (en) | 2002-06-28 | 2002-07-18 | Novapharm Research (Australia) Pty Ltd | Water treatment |
US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
WO2004026896A2 (fr) | 2002-09-23 | 2004-04-01 | Medivir Ab | Inhibiteurs de la serine protease ns-3 du virus de l'hepatite c |
EP1408031A1 (fr) | 2002-10-09 | 2004-04-14 | 3 D Gene Pharma | Derivés de pyrolidine comme médicaments contre Hepatitis C |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
DK1558730T3 (da) | 2002-10-29 | 2008-05-26 | Boehringer Ingelheim Int | Inhibitorresistent HCV-NS3-protease |
WO2004072243A2 (fr) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la serine protease de l'hepatite c |
JP4682140B2 (ja) | 2003-03-05 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類縁体 |
WO2004101605A1 (fr) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Composes d'inhibition de l'hepatite c |
UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
NZ543250A (en) | 2003-04-02 | 2008-12-24 | Boehringer Ingelheim Int | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
EP1615947A2 (fr) | 2003-04-10 | 2006-01-18 | Boehringer Ingelheim International GmbH | Procede de preparation de composes macrocycliques |
WO2004092161A1 (fr) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc |
WO2004094452A2 (fr) | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Peptide d'isoquinoleine macrocyclique inhibiteurs du virus de l'hepatite c |
WO2004093798A2 (fr) | 2003-04-18 | 2004-11-04 | Enanta Pharmaceuticals, Inc. | Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c |
DE602004010137T2 (de) | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
WO2004113365A2 (fr) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la tripeptide hepatite c serine protease |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
MXPA06003141A (es) * | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c. |
DE10344793A1 (de) | 2003-09-26 | 2005-04-14 | Rieter Automatik Gmbh | Vorrichtung zum Granulieren thermoplastischer Kunststoffe |
SE0400199D0 (sv) * | 2004-01-30 | 2004-01-30 | Medivir Ab | HCV Protease inhbitors |
NZ548740A (en) * | 2004-01-30 | 2010-06-25 | Medivir Ab | HCV NS-3 Serine protease inhibitors |
CA2577831A1 (fr) * | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Procede de fabrication d'inhibiteurs de protease hcv macrocycliques |
CA2617096C (fr) * | 2005-07-29 | 2013-12-24 | Tibotec Pharmaceuticals Ltd. | Inhibiteurs macrocycliques du virus de l'hepatite c |
PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
BRPI0613933A2 (pt) * | 2005-07-29 | 2011-02-22 | Medivir Ab | inibidores macrocìlicos do vìrus da hepatite c |
TWI393723B (zh) | 2005-07-29 | 2013-04-21 | Tibotec Pharm Ltd | C型肝炎病毒之大環抑制劑(九) |
TWI383980B (zh) | 2005-07-29 | 2013-02-01 | Tibotec Pharm Ltd | C型肝炎病毒之大環抑制劑 |
JO2768B1 (en) * | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
MY142972A (en) * | 2005-07-29 | 2011-01-31 | Tibotec Pharm Ltd | Macrocyclic inhibitors of hepatitis c virus |
PE20070210A1 (es) * | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
ES2373685T3 (es) * | 2005-07-29 | 2012-02-07 | Tibotec Pharmaceuticals | Inhibidores macrocíclicos del virus de la hepatitis c. |
BRPI0614620A2 (pt) * | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para preparar os referidos compostos, combinação e composição farmacêutica |
PT2118098E (pt) | 2007-02-01 | 2014-12-09 | Janssen R & D Ireland | Formas polimórficas de um inibidor macrocíclico do hcv |
KR20130057990A (ko) | 2010-04-13 | 2013-06-03 | 얀센 파마슈티칼즈, 인코포레이티드 | 마크로사이클릭 hcv 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물 |
US8402690B2 (en) | 2010-09-09 | 2013-03-26 | Sterling International Inc. | Bedbug trap |
-
2006
- 2006-07-26 PE PE2006000910A patent/PE20070211A1/es active IP Right Grant
- 2006-07-28 CN CN201210389139.0A patent/CN103030636B/zh not_active Expired - Fee Related
- 2006-07-28 SG SG201005140-7A patent/SG163617A1/en unknown
- 2006-07-28 GT GT200600339A patent/GT200600339A/es unknown
- 2006-07-28 SI SI200632004T patent/SI2322516T1/sl unknown
- 2006-07-28 AT AT06778071T patent/ATE494288T1/de active
- 2006-07-28 ME MEP-2015-208A patent/ME02415B/me unknown
- 2006-07-28 EP EP10187197.8A patent/EP2322516B1/fr active Active
- 2006-07-28 CN CN2006800269505A patent/CN101228169B/zh not_active Expired - Fee Related
- 2006-07-28 MY MYPI20063669A patent/MY144217A/en unknown
- 2006-07-28 JP JP2008523382A patent/JP4797067B2/ja not_active Expired - Fee Related
- 2006-07-28 AU AU2006274865A patent/AU2006274865B2/en not_active Ceased
- 2006-07-28 US US11/632,102 patent/US8148399B2/en not_active Expired - Fee Related
- 2006-07-28 EP EP15158049.5A patent/EP2937339A1/fr not_active Withdrawn
- 2006-07-28 BR BRPI0614654-6A patent/BRPI0614654B1/pt not_active IP Right Cessation
- 2006-07-28 RS RS20110145A patent/RS51743B/en unknown
- 2006-07-28 SI SI200630969T patent/SI1912999T1/sl unknown
- 2006-07-28 DK DK06778071.8T patent/DK1912999T3/da active
- 2006-07-28 AP AP2008004301A patent/AP2406A/xx active
- 2006-07-28 PT PT101871978T patent/PT2322516E/pt unknown
- 2006-07-28 ME MEP-2011-58A patent/ME01231B/fr unknown
- 2006-07-28 PL PL06778071T patent/PL1912999T3/pl unknown
- 2006-07-28 KR KR1020087003598A patent/KR101059419B1/ko active IP Right Grant
- 2006-07-28 HU HUE10187197A patent/HUE027156T2/en unknown
- 2006-07-28 DE DE602006019439T patent/DE602006019439D1/de active Active
- 2006-07-28 DK DK10187197.8T patent/DK2322516T3/en active
- 2006-07-28 PL PL10187197T patent/PL2322516T3/pl unknown
- 2006-07-28 AR ARP060103304A patent/AR055359A1/es not_active Application Discontinuation
- 2006-07-28 NZ NZ564550A patent/NZ564550A/en not_active IP Right Cessation
- 2006-07-28 CN CN201210047344.9A patent/CN102627639B/zh not_active Expired - Fee Related
- 2006-07-28 TW TW095127587A patent/TWI358411B/zh not_active IP Right Cessation
- 2006-07-28 PT PT06778071T patent/PT1912999E/pt unknown
- 2006-07-28 EP EP06778071A patent/EP1912999B1/fr active Active
- 2006-07-28 ES ES10187197.8T patent/ES2555230T3/es active Active
- 2006-07-28 WO PCT/EP2006/064820 patent/WO2007014926A1/fr active Application Filing
- 2006-07-28 EA EA200800476A patent/EA015131B1/ru not_active IP Right Cessation
- 2006-07-28 RS RS20150857A patent/RS54473B1/en unknown
- 2006-07-28 CA CA002616580A patent/CA2616580C/fr not_active Expired - Fee Related
- 2006-07-28 UY UY29703A patent/UY29703A1/es not_active Application Discontinuation
- 2006-07-29 SV SV2006002642A patent/SV2008002642A/es unknown
-
2007
- 2007-12-18 IL IL188227A patent/IL188227A/en not_active IP Right Cessation
-
2008
- 2008-01-28 HN HN2008000134A patent/HN2008000134A/es unknown
- 2008-01-28 ZA ZA2008/00857A patent/ZA200800857B/en unknown
- 2008-01-28 EC EC2008008150A patent/ECSP088150A/es unknown
- 2008-01-29 NI NI200800036A patent/NI200800036A/es unknown
- 2008-02-29 CR CR9783A patent/CR9783A/es unknown
- 2008-02-29 NO NO20081073A patent/NO342393B1/no not_active IP Right Cessation
- 2008-06-18 HK HK08106768.9A patent/HK1116771A1/xx not_active IP Right Cessation
-
2011
- 2011-04-01 HR HR20110237T patent/HRP20110237T1/hr unknown
- 2011-04-05 CY CY20111100360T patent/CY1112006T1/el unknown
- 2011-08-03 US US13/197,226 patent/US8153800B2/en not_active Expired - Fee Related
-
2012
- 2012-03-06 US US13/412,997 patent/US8349869B2/en not_active Expired - Fee Related
- 2012-11-28 US US13/687,037 patent/US8741926B2/en not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/832,166 patent/US8754106B2/en not_active Expired - Fee Related
- 2013-10-09 HK HK13111375.7A patent/HK1183872A1/zh not_active IP Right Cessation
-
2014
- 2014-05-23 US US14/285,854 patent/US9040562B2/en active Active
- 2014-10-07 HU HUS1400054C patent/HUS1400054I1/hu unknown
- 2014-10-07 LU LU92568C patent/LU92568I2/fr unknown
- 2014-10-07 CY CY2014044C patent/CY2014044I1/el unknown
-
2015
- 2015-04-13 US US14/684,649 patent/US9353103B2/en not_active Expired - Fee Related
- 2015-07-30 IL IL240244A patent/IL240244A0/en unknown
- 2015-12-04 HR HRP20151326TT patent/HRP20151326T1/hr unknown
- 2015-12-21 CY CY20151101162T patent/CY1117392T1/el unknown
-
2016
- 2016-04-25 US US15/137,997 patent/US9623022B2/en not_active Expired - Fee Related
-
2017
- 2017-03-09 US US15/454,911 patent/US9856265B2/en not_active Expired - Fee Related
-
2018
- 2018-10-24 NO NO2018037C patent/NO2018037I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92568I2 (fr) | Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir | |
LU93312I2 (fr) | Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate | |
LU92446I2 (fr) | Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium | |
LU93327I2 (fr) | Opicapone ou un sel pharmaceutiquement acceptable de celui-ci | |
LU92137I2 (fr) | Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables | |
NL2000323A1 (nl) | Pyrimidine-derivaten. | |
DE602006000920D1 (de) | Zündvorrichtung | |
DK1787519T3 (da) | Skoldeapparat | |
DE602006001324D1 (de) | Übertragungswerkzeug | |
FI20055498A0 (fi) | Sulfonamidijohdannaisia | |
ITMI20050051A1 (it) | Fotodiodio organico di poli-9,9-diottil-fluorene | |
DE502006006543D1 (de) | Werkzeughalter | |
DE602006007885D1 (de) | Kleiderbügel | |
IL187894A0 (en) | Alkyl sulfonamide derivatives | |
EE00524U1 (et) | Teisaldatav soolakamber | |
ES1061996Y (es) | Arado de laboreo entre cepas. | |
ES1061247Y (es) | Bloque de conexiones intercambiables. | |
GB0523080D0 (en) | Masonry splitting | |
ES1058623Y (es) | Maquina conformadora de bordillos. | |
TR200503506A3 (tr) | Tilfir mala. | |
ES1059674Y (es) | Cubo de basura prensa-envases. | |
UA11923S (uk) | Настінний годинник-вмістина | |
ES1062106Y (es) | Cuchara semicircular. | |
FI20050529A0 (fi) | Siirtoseinäjärjestelmä | |
ES1059827Y (es) | Gancho de acoplamiento. |